Amended Quarterly Report (10-q/a)
15 November 2017 - 1:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
Amendment No. 1
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE
|
SECURITIES EXCHANGE ACT OF 1934
|
|
For the quarterly period ended
June 30, 2017
|
|
OR
|
|
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
|
SECURITIES EXCHANGE ACT OF 1934
|
|
For the transition period from
to
|
Commission File Number 000-30929
MUSTANG BIO, INC.
(Exact name of registrant as specified
in its charter)
Delaware
(State or other jurisdiction of incorporation
or organization)
|
47-3828760
(I.R.S. Employer Identification No.)
|
2 Gansevoort Street, 9th Floor
New York, New York 10014
(Address including zip code of principal
executive offices)
(781) 652-4500
(Registrant's telephone number, including
area code)
(Former name, former address and former
fiscal year, if changed since last report)
Indicate by check mark whether the registrant:
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes
x
No
¨
Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for
such shorter period that the registrant was required to submit and post such files). Yes
x
No
¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer
|
¨
|
Accelerated filer
|
x
|
Non-accelerated filer
|
o
(Do not check if a smaller reporting company)
|
Smaller reporting company
|
¨
|
|
|
Emerging growth company
|
x
|
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
¨
No
x
Class of Common Stock
|
|
Outstanding Shares as of November 13, 2017
|
Class A Common Stock, $0.0001 par value
|
|
1,000,000
|
Common Stock, $0.0001 par value
|
|
25,232,139
|
EXPLANATORY NOTE
MUSTANG BIO, INC.
(the “Company”) is filing this amendment (the “Form 10-Q/A”) to our Quarterly Report on Form 10-Q for
the quarter ended June 30, 2017 (the “Form 10-Q”), filed with the U.S. Securities and Exchange Commission on
August 14, 2017, solely to correct a change to the exhibits. While the exhibit list of the Form 10-Q correctly included
Exhibits 10.1, 10.2, and 10.3, we received further comments from the Securities and Exchange Commission on our Confidential
Treatment Request that require additional revisions to the documents. They are now being filed with this 10-Q/A.
This Form 10-Q/A should be read in conjunction
with the original Form 10-Q, which continues to speak as of the date of the Form 10-Q. Except as specifically noted above, this
Form 10-Q/A does not modify or update disclosures in the original Form 10-Q. Accordingly, this Form 10-Q/A does not reflect events
occurring after the filing of the Form 10-Q or modify or update any related or other disclosures.
ITEM 6. EXHIBITS
The exhibits
listed on the Exhibit Index are included with this report.
|
^
|
Confidential treatment
has been requested with respect to omitted portions of this exhibit.
|
Signatures
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
MUSTANG BIO, INC.
|
|
|
|
November 14, 2017
|
By:
|
/s/ Manuel Litchman
|
|
|
Manuel Litchman, M.D., President
and
Chief Executive Officer (Principal
Executive Officer)
|
|
|
|
|
By:
|
/s/ David J. Horin
|
|
|
David J. Horin
Interim Chief Financial Officer
(Principal Financial Officer)
|
Mustang Bio (NASDAQ:MBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Mustang Bio (NASDAQ:MBIO)
Historical Stock Chart
From May 2023 to May 2024